Search results for "Tumor-Infiltrating"

showing 10 items of 78 documents

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?

2019

e14035 Background: The immune response to melanoma has been shown to be locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk (infiltrating the entire base of the invasive tumor), non-brisk (infiltrating only focally) and absent. Several studies showed that greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and a higher survival rate. Since recent studies revealed an association between PD-1/PD-L1 expression levels and tumor response, the aim of our study was to investigate the correlation between plasma PD-1 and presence/absence/class of TILs in metastatic melanoma patients. Methods: The plasm…

Cancer ResearchMetastatic melanomaTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemschemical and pharmacologic phenomenamedicine.disease03 medical and health sciences0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesisCancer researchmedicineplasma PD-1 tumor-infiltrating lymphocytes metastatic melanomabusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Nanofitins targeting heat shock protein 110: an innovative immunotherapeutic modality in cancer.

2021

The presence of an inactivating heat shock protein 110 (HSP110) mutation in colorectal cancers has been correlated with an excellent prognosis and with the ability of HSP110 to favor the formation of tolerogenic (M2-like) macrophages. These clinical and experimental results suggest a potentially powerful new strategy against colorectal cancer: the inhibition of HSP110. In this work, as an alternative to neutralizing antibodies, Nanofitins (scaffold ~7 kDa proteins) targeting HSP110 were isolated from the screening of a synthetic Nanofitin library, and their capacity to bind (immunoprecipitation, biolayer interferometry) and to inhibit HSP110 was analyzed in vitro and in vivo. Three Nanofiti…

Cancer ResearchMice03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemPeptide LibraryIn vivoCell Line TumorHeat shock proteinTumor MicroenvironmentmedicineAnimalsHumansCytotoxic T cellHSP110 Heat-Shock Proteinssmall peptide moleculesTumor microenvironmentanticancer targeted therapybiologyChemistryMacrophagesCancer[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesmedicine.diseaseXenograft Model Antitumor AssaysPeptide FragmentsIn vitro3. Good healthNanofitinsOncologyPositron-Emission Tomography030220 oncology & carcinogenesisbiology.proteinCancer researchFemaleAntibodyColorectal NeoplasmsHSP110
researchProduct

Investigation of the immune infiltrate of melanoma metastases under immune checkpoint inhibition.

2017

9570 Background: Tumor infiltrating lymphocytes (TIL) play a crucial role in the therapeutic impact of immune checkpoint blockers. Methods: We investigated metastases from 56 melanoma patients before and during treatment with immune checkpoint blockers (i) immunohistochemically, (ii) with TCR repertoire profiling and (iii) analysis of the transcriptome. The patients were treated with ipilimumab (n = 25) or pembrolizumab (n = 23) or ipilimumab/nivolumab (n = 7); half of them had a disease control, the other half progressed as best response to treatment. Results: In contrast to previous reports immunohistochemical analysis of the immune infiltrate revealed no significant difference in the nu…

Cancer ResearchOncologyTumor-infiltrating lymphocytesbusiness.industryMelanomamedicineCancer researchchemical and pharmacologic phenomenamedicine.diseasebusinessImmune checkpointImmune infiltrateJournal of Clinical Oncology
researchProduct

Enhanced expression of ELAM-1 on endothelium of renal cell carcinoma compared to the corresponding normal renal tissue

1999

Abstract Renal cell carcinoma (RCC) has been shown to respond to an immunological therapy with tumor infiltrating lymphocytes (TIL), which accumulate in RCC at a higher density than in normal renal tissue, suggesting that there is selective tumor invasion. Since invasion of TIL into the malignant tissue is mediated by adhesion molecules, we examined the different expression of the adhesion molecule endothelial-leukocyte-adhesion-molecule-1 (ELAM-1) on endothelial cells of RCC versus normal renal tissue. For a specific quantification, the level of ELAM-1 mRNA was investigated by both semi-quantitative reverse transcription–polymerase chain reaction (RT–PCR) and Northern blot analysis and ref…

Cancer ResearchPathologymedicine.medical_specialtyEndotheliumBiologyKidneyurologic and male genital diseasesImmunoenzyme TechniquesRenal cell carcinomaGene expressionmedicineCarcinomaHumansRNA MessengerNorthern blotCarcinoma Renal CellDNA PrimersKidneyReverse Transcriptase Polymerase Chain ReactionTumor-infiltrating lymphocytesCell adhesion moleculeBlotting Northernmedicine.diseaseKidney Neoplasmsmedicine.anatomical_structureOncologyCancer researchEndothelium VascularE-SelectinCancer Letters
researchProduct

Exome Sequencing to Predict Neoantigens in Melanoma

2015

Abstract The ability to use circulating peripheral blood cells and matched tumor sequencing data as a basis for neoantigen prediction has exciting possibilities for application in the personalized treatment of cancer patients. We have used a high-throughput screening approach, combining whole-exome sequence data, mRNA microarrays, and publicly available epitope prediction algorithm output to identify mutated proteins processed and displayed by patient tumors and recognized by circulating immune cells. Matched autologous melanoma cell lines and peripheral blood mononuclear cells were used to create mixed lymphocyte tumor cell cultures, resulting in an expansion of tumor-reactive T cells to u…

Cancer Researchbusiness.industryMelanomaLymphocyteImmunologyEpitopes T-LymphocyteDendritic cellCD8-Positive T-Lymphocytesmedicine.diseasePeripheral blood mononuclear cellEpitopeInterferon-gammaLymphocytes Tumor-Infiltratingmedicine.anatomical_structureImmune systemAntigenAntigens NeoplasmMutationImmunologyHumansMedicineExomebusinessMelanomaExome sequencingCancer Immunology Research
researchProduct

Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer.

2022

Abstract Background Although high T cell density is a strong favourable prognostic factor in colorectal cancer, the significance of the spatial distribution of T cells is incompletely understood. We aimed to evaluate the prognostic significance of tumour cell-T cell co-localisation and T cell densities. Methods We analysed CD3 and CD8 immunohistochemistry in a study cohort of 983 colorectal cancer patients and a validation cohort (N = 246). Individual immune and tumour cells were identified to calculate T cell densities (to derive T cell density score) and G-cross function values, estimating the likelihood of tumour cells being co-located with T cells within 20 µm radius (to derive T cell p…

Cancer ResearchkasvaimetIDENTIFICATIONtumour immunologyT-LymphocytesBIOMARKERS3122 Cancerscolorectal cancerCD8-Positive T-Lymphocytes3126 Surgery anesthesiology intensive care radiologyPrognosisT-imusolutimmunohistokemiaLymphocytes Tumor-InfiltratingOncologyBRAF MUTATIONBiomarkers TumorHumanssyöpätauditLymphocyte CountColorectal NeoplasmsIMMUNOSCOREcancer microenvironmentpaksusuolisyöpäBritish journal of cancer
researchProduct

mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA

2013

Abstract Vaccination with in vitro transcribed RNA encoding tumor antigens is an emerging approach in cancer immunotherapy. Attempting to further improve RNA vaccine efficacy, we have explored combining RNA with immunomodulators such as rapamycin. Rapamycin, the inhibitor of mTOR, was used originally for immunosuppression. Recent reports in mouse systems, however, suggest that mTOR inhibition may enhance the formation and differentiation of the memory CD8+ T-cell pool. Because memory T-cell formation is critical to the outcome of vaccination aproaches, we studied the impact of rapamycin on the in vivo primed RNA vaccine-induced immune response using the chicken ovalbumin-expressing B16 mela…

Cancer Researchmedicine.medical_treatmentImmunologyMelanoma ExperimentalCD8-Positive T-LymphocytesBiologyCancer VaccinesLymphocytes Tumor-InfiltratingImmune systemAntigenCancer immunotherapyAntigens NeoplasmIn vivomedicineAnimalsRNA NeoplasmPI3K/AKT/mTOR pathwaySirolimusVaccines SyntheticAntibiotics AntineoplasticTOR Serine-Threonine KinasesVaccinationRNACell DifferentiationCombined Modality TherapyMice Inbred C57BLVaccinationImmunologyCancer researchFemaleDrug Screening Assays AntitumorImmunologic MemoryCD8Cancer Immunology Research
researchProduct

Immune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells

2014

Immune control of hepatocellular carcinoma (HCC) is executed by effector immune cells, which efficiently eliminate malignant transformed cells. However, progression of HCC clearly documents failure of tumor immune control, which led to the concept of immune subversion by the tumor environment. Particularly tumor-associated stromal cells cooperate within an inflammatory network, which is responsible for immune privilege. The stromal cell composition matures during tumor growth and is derived from surrounding noncancerous tissue or from circulating cells recruited to the tumor site. Therefore, immunosuppressive stromal cells represent heterogeneous cell lineages, including myeloid cells, lymp…

Carcinoma HepatocellularStromal cellmedicine.medical_treatmentAdaptive ImmunityBiologyLymphocytes Tumor-InfiltratingImmune systemCancer immunotherapyImmune privilegeTumor MicroenvironmentLymph node stromal cellmedicineAnimalsHumansTumor microenvironmentHepatologyLiver Neoplasmsbiochemical phenomena metabolism and nutritionAcquired immune systemImmunity InnateB-1 cellImmunologyCytokinesbacteriaTumor EscapeImmunotherapyStromal CellsSignal TransductionSeminars in Liver Disease
researchProduct

Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia

2011

AbstractTherapeutic strategies combining the induction of effective antitumor immunity with the inhibition of the mechanisms of tumor-induced immunosuppression represent a key objective in cancer immunotherapy. Herein we demonstrate that effector/memory CD4+ T helper-1 (Th-1) lymphocytes, in addition to polarizing type-1 antitumor immune responses, impair tumor-induced CD4+CD25+FoxP3+ regulatory T lymphocyte (Treg) immunosuppressive function in vitro and in vivo. Th-1 cells also inhibit the generation of FoxP3+ Tregs from naive CD4+CD25−FoxP3− T cells by an interferon-γ–dependent mechanism. In addition, in an aggressive mouse leukemia model (12B1), Th-1 lymphocytes act synergistically with …

Cell Extractsmedicine.medical_treatmentBlotting WesternImmunologyMice NudeEnzyme-Linked Immunosorbent Assaychemical and pharmacologic phenomenaMice SCIDBiologyCancer VaccinesT-Lymphocytes RegulatoryBiochemistryInterferon-gammaMiceLymphocytes Tumor-InfiltratingImmune systemCancer immunotherapyAntigenTumor Cells CulturedmedicineAnimalsInterferon gammaIL-2 receptorImmunobiologyMice Inbred BALB CLeukemia ExperimentalFOXP3hemic and immune systemsForkhead Transcription FactorsDendritic CellsT-Lymphocytes Helper-InducerCell BiologyHematologyT lymphocyteFlow Cytometrymedicine.diseaseMice Inbred C57BLLeukemiaImmunologyImmunologic MemoryMolecular ChaperonesT-Lymphocytes Cytotoxicmedicine.drugBlood
researchProduct

Lymphokine activated killer cells.

1989

Various subpopulations of human leukocytes may be induced by lymphokines to exert cytotoxic activity. In man major histocompatibility complex non-restricted tumor cell lysis by interleukin-2 (IL-2) induced peripheral blood lymphocytes is attributed mainly to natural killer cells. These T cell receptor negative large granular lymphocytes are called lymphokine activated killer (LAK) cells. In order to explore the potential of LAK cells in tumor therapy, several clinical studies have been conducted, using IL-2 alone or in combination with ex vivo IL-2-activated peripheral blood lymphocytes. Objective responses have reproducibly been achieved only in renal cell carcinoma and malignant melanoma …

Cytotoxicity ImmunologicLymphokine-activated killer cellTumor-infiltrating lymphocytesmedicine.medical_treatmentLymphokineHematologyGeneral MedicineImmunotherapyBiologyNatural killer T cellMajor histocompatibility complexLymphocyte ActivationTumor antigenKiller Cells NaturalImmunologymedicinebiology.proteinCytotoxic T cellAnimalsHumansInterleukin-2Killer Cells Lymphokine-ActivatedBlut
researchProduct